Skip to content
Search

Latest Stories

Two universities join forces to address pharmacist shortage in south west of England

Two universities join forces to address pharmacist shortage in south west of England

A survey revealed that the South West has the highest vacancy rate for community pharmacist roles in England. 

The University of Bath is offering its MPharm programme at the University of Plymouth to address community pharmacist workforce shortages, particularly in the south west of England, which has the highest vacancy rate for pharmacists in the country.


The two universities have collaborated with NHS England to expand the MPharm programme, making it available at the University of Plymouth from September 2024.

Students at Plymouth will study the same course content as those studying Pharmacy in Bath, and will graduate with a University of Bath degree.

Julian Chaudhuri, pro-vice chancellor (education) at the University of Bath, told the publication that the collaboration will help increase the numbers of pharmacy graduates in the south west, and significantly contribute to healthcare within the region.

The University of Plymouth’s deputy vice chancellor, John Curnow, is hopeful that the partnership between Plymouth, Bath and NHS England will make a “tremendously positive difference to the health and wellbeing of people in our region and beyond.”

According to the 2022 Community pharmacy workforce survey report, the Somerset Integrated Care System (ICS) area has the highest vacancy rate for community pharmacist roles in England, with 33 per cent (77 of 237) of full-time equivalent (FTE) positions unfilled, including locum and relief pharmacists.

The data published by NHSE in August 2023 also highlighted the urgent need for more pharmacists in Bath and North East Somerset, Swindon and Wiltshire ICS area, with 25% (72 of 284) of FTE positions unfilled, as well as in Devon ICS area which had a vacancy rate of 20% (84 of 418).

Further, the survey revealed that Somerset ICS area had just five FTE foundation pharmacists in post, one of the lowest numbers of trainees in post in the country, the Pharmaceutical Journal reported.

The University of Plymouth is already inviting applications for the 2024 MPharm course.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less